Lipid profilein psoriatic arthritis. Frequency and association with disease activity

SAVIO V; TISSERA Y; QUAGLIA MI; ALBIERO JA; ALONSO CG; DEMARCHI M; MALDINI C; GOBBI C; YORIO M; MARTINI AC; CASTRILLÓN ME; ALBA A

Frankfurt

Congreso; Annual Congress of EULAR 2020; 2020

Background:Psoriatic arthritis (PsA) is a chronic inflammatory disease associated with higher riskof cardiovascular events and metabolic syndrome. The inflammation not onlyaccelerates atherosclerosis, but also may influence cardiovascular (CV) risk factorssuch as lipid profile, blood pressure and insulin resistance. Lipid profile has previouslybeen studied in PsA, however this association is still controversial.Objectives:To study the frequency of altered lipid profile in patients with PsA and its association withdisease activity.Methods:We studied all the patients with diagnosis of PsA who consecutively attended toRheumatology Unit at Cordoba Hospital from July 2018 to December 2019. PsA wasdiagnosed according CASPAR criteria. Clinical and laboratory data were collected.The activity of the disease was evaluated by PASI, MDA and DAPSA. Quantitativevariables will be expressed in median and 1st and 3rd interquartile; qualitative variablesexpressed in frequency and percentage. Correlation analysis was calculated usingSpearman?s rank correlation coefficient. P<0.05 was considered statisticallysignificant.Results:42 PsA patients were included. Mean age was 56 years old (47.25-62.75) and 54.76%were female (n=23). 92.86% (n=39) of the patients had plaque Psoriasis and 87.8%(n=36) had peripheral joint involvement.Frequency of comorbidities in PsA are shown in Graphic 1. 31 (73.8%) of the patientswere treated with topical therapy, 3 (7.14%) with phototherapy, 31 (73.8%) withMethotrexate and 17 (41.46%) with biologics and JAK inhibitor. Activity Disease Indexand Lipid profile are shown in Table 1 and 2.There was not association between Apo B/Apo A coefficient with DAPSA (rho=0.013;p=0.940) and MDA (rho=-0.029; p=0.867).Conclusion:In spite of the presence of cardiovascular factors in the majority of PsA patients, lipidprofile is not correlated with disease activity in this population.